Literature DB >> 15771329

The prevalence of rheumatic diseases in the elderly in developed countries and its evolution over time.

Marjorie M Mariller1, Brigitte Santos-Eggimann.   

Abstract

OBJECTIVES: This study aims at evaluating the prevalence of rheumatic diseases in the elderly and its evolution over time.
METHODS: We present a systematic international literature review of the prevalence of rheumatic diseases in the elderly and its evolution over time.
RESULTS: The estimated current prevalence of rheumatic diseases among people aged 65 and more varies between 41% and 53%, and is similar to estimated prevalence rates in studies performed before 1990 (35-55%). The prevalence is high and seems to increase rapidly with age. Furthermore, women suffer more frequently from rheumatic diseases than men.
CONCLUSION: The selected studies included a large range of methods, making comparisons difficult. However, estimates of the prevalence of rheumatic diseases in the elderly appear to be homogeneous in different countries and stable since 1980.

Entities:  

Mesh:

Year:  2005        PMID: 15771329     DOI: 10.1007/s00038-004-3139-2

Source DB:  PubMed          Journal:  Soz Praventivmed        ISSN: 0303-8408


  2 in total

1.  Discordance between self-reported arthritis and musculoskeletal signs and symptoms in older women.

Authors:  Tkt Lo; Lynne Parkinson; Michelle Cunich; Julie Byles
Journal:  BMC Musculoskelet Disord       Date:  2016-12-01       Impact factor: 2.362

2.  A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases.

Authors:  Patrícia Shu Kurizky; Fernanda Ferraço Marianelli; Mariana Vicente Cesetti; Giovanni Damiani; Raimunda Nonata Ribeiro Sampaio; Lais Mitsue Tanaka Gonçalves; Carlos Augusto Felipe de Sousa; Sofia Sales Martins; Sebastian Vernal; Licia Maria Henrique da Mota; Ciro Martins Gomes
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-05-11       Impact factor: 1.846

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.